International Vaccine Institute
SNU Research Park
Seoul, 08826 Korea
Center Director: Dr. Jerome Kim
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea.
Institut Pasteur Korea, (IPK)
16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488 Rep. of Korea
Center Director: Dr. YoungMee Jee
Member Researchers: Seungtaek Kim, Euiho Kim, Marc P. Windisch, Regis Grailhe, Inheo Choi, Spencer Shorte
The Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting-edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and contributes to Korea’s future scientific resources through research, education, and technological innovation. The institute was established in April 2004 in collaboration with the Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science and ICT (MSIT). IPK also has a great supporter in the Gyeonggi Provincial government. IPK is a private, non-profit foundation with four core missions of public interest – Research, Education, Public Health, and Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships. As a member of the Institut Pasteur International Network (IPIN), IPK has excellent opportunities for scientific cooperation with other 31 IPIN members located in 25 countries. IPK combines front-line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases. IPK currently focuses on global infectious diseases that represent today’s health challenges, such as emerging zoonotic and vector-borne diseases such as SARS-CoV2, MERS-CoV, Severe Fever with Thrombocytopenia Syndrome (SFTS), Zika virus, Dengue virus, and Ebola virus, as well as hepatitis viruses (B, C, D, and E), influenza, and has a comprehensive plan for therapeutics research on emerging viral diseases (Disease X).